罕见儿科疾病优先审评券（PRV）项目：加速批准的制造策略（第一部分）

Nathan Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.

This webinar, “Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval,” is moderated by Nathan Edwards, engagement manager with ARYA Consulting Partners, with guests Elisabeth Gardiner, chief scientific officer, Tevard Biosciences; and Donny Xu, a policy analyst at the RTW Institute. In Part 1, the guests explain the history of the Rare Pediatric Disease Priority Review Voucher (PRV) Program and the benefits and challenges of going through the PRV process.

Edwards opens the discussion with a review of rare disease treatment development, noting that roughly 25–30 million Americans live with one of about 7,000 rare diseases, yet only about 5% have an approved therapy. The market is growing faster than non-rare segments (projected ~11.6% CAGR), and despite recent FDA flexibility initiatives (rare disease evidence principles, the plausible mechanism framework), approximately 80% of complete response letters since 2025 have gone to orphan-designated drugs, with roughly half tied to chemistry, manufacturing, and controls (CMC) deficiencies and 20% to trial design issues.

The core discussion centers on the Rare Pediatric Disease PRV Program. Xu traced its history from its creation in 2007 for tropical diseases, the extenion to rare pediatric diseases in 2012, reauthorizations in 2016 and 2020, then a lapse in 2024 for 14 months before being reinstated in February 2026 and extended to September 2029. Both guests stressed the mismatch between the program's 4-year reauthorization cycle and the 10- to 12-year drug development timeline, with Xu advocating for permanence or at least a 10-year cycle.

Gardiner notes Tevard plans around PRV eligibility in both the US and the European Union but doesn’t rely on it. She says scientific and therapeutic fit drive program decisions, not the voucher alone. She highlights the PRV’s unique value as a transferable, sellable asset. Vouchers have sold for approximately $200–220 million, up from approximately $100 million 5 to 10 years ago, the experts note. This is useful for companies, including large pharma buying vouchers unrelated to rare disease, to accelerate review timelines (10 months to 6 months) for other assets.

Both guests emphasize that strong science, safety data, and manufacturing/CMC readiness must come before seeking a PRV, because the voucher is only awarded after approval and the program’s future isn’t guaranteed. They discussed their belief that companies should pursue multiple parallel designations (orphan drug, fast track, breakthrough therapy, PRV) when eligible, because each offers different benefits, such as exclusivity, user fee waivers, expedited review, or the PRV’s unique cash value.

The conversation closes on international regulatory strategy: sequencing designation requests across the FDA, European Medicines Agency, Medicines and Healthcare Products Regulatory Agency in the UK, and Japan depends on patient population location and market-specific designations, and genetic testing requirements vary by country, affecting trial site selection. Donny also touches on China’s investigator-initiated trial model and Australia’s tiered clinical trial approval/clinical trial notification pathways as faster alternatives for first-in-human trials worth FDA’s consideration.

In Part 2, the speakers will dive deeper into CMC challenges and navigating regulations.

Click the video above to watch Part 1 of the webinar.

Related to this article